Presentation Outline ICHP Annual Meeting September 13-15

Media‐Worthy Trial Assessment #1:
ASPIRIN FOR PREVENTING THE
RECURRENCE OF VENOUS
THROMBOEMBOLISM (WARFASA
TRIAL)
N Engl J Med. 2012;366(21):1959-1967.
Aspirin
• Most commonly studied antiplatelet drug
• Treatment and prevention of MI and stroke
– ↓ vascular death by ~15%
– ↓ nonfatal f lvascular l events by b ~30% 30%
• Well‐known prevention What about of arterial events
CHEST. 2012;141(2_suppl):e89S-e119S.
venous events?
8/30/2012
2